462 related articles for article (PubMed ID: 17697056)
1. Premixed insulin treatment for type 2 diabetes: analogue or human?
Garber AJ; Ligthelm R; Christiansen JS; Liebl A
Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
[TBL] [Abstract][Full Text] [Related]
2. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues.
Rolla AR; Rakel RE
Clin Ther; 2005 Aug; 27(8):1113-25. PubMed ID: 16199240
[TBL] [Abstract][Full Text] [Related]
3. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
4. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.
Rolla A
Am J Med; 2008 Jun; 121(6 Suppl):S9-S19. PubMed ID: 18514090
[TBL] [Abstract][Full Text] [Related]
7. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control.
Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S
Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637
[TBL] [Abstract][Full Text] [Related]
8. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
[TBL] [Abstract][Full Text] [Related]
9. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus.
Cucinotta D; Russo GT
Expert Opin Pharmacother; 2009 Dec; 10(17):2905-11. PubMed ID: 19929709
[TBL] [Abstract][Full Text] [Related]
10. Premixed insulin analogues for the treatment of diabetes mellitus.
Garber AJ
Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
[TBL] [Abstract][Full Text] [Related]
11. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
12. Insulin therapy in type 2 diabetes: what is the evidence?
van Avendonk MJ; Rutten GE
Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375
[TBL] [Abstract][Full Text] [Related]
13. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
14. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
Ilag LL; Kerr L; Malone JK; Tan MH
Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
Bott S; Tusek C; Heinemann L; Friberg HH; Heise T
Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159
[TBL] [Abstract][Full Text] [Related]
16. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
Hermansen K; Dornhorst A; Sreenan S
Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
Home PD
Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
[TBL] [Abstract][Full Text] [Related]
18. Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.
Tibaldi JM
Clin Ther; 2011 Nov; 33(11):1630-42. PubMed ID: 22030443
[TBL] [Abstract][Full Text] [Related]
19. Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.
Schmoelzer I; de Campo A; Pressl H; Stelzl H; Dittrich P; Oettl K; Wascher TC
Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):176-81. PubMed ID: 15789278
[TBL] [Abstract][Full Text] [Related]
20. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
Khutsoane D; Sharma SK; Almustafa M; Jang HC; Azar ST; Danciulescu R; Shestakova M; Ayad NM; Guler S; Bech OM;
Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
